Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

94.47USD
22 Nov 2017
Change (% chg)

$-0.21 (-0.22%)
Prev Close
$94.68
Open
$94.79
Day's High
$95.39
Day's Low
$94.24
Volume
796,629
Avg. Vol
1,615,988
52-wk High
$98.20
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

AbbVie, on conf call, says we need to see HCV market sort itself out
Friday, 27 Oct 2017 12:30pm EDT 

Oct 27 (Reuters) - Abbvie Inc ::AbbVie CEO, on conf call, says we need to see HCV market sort itself out.AbbVie CEO, on conf call, says psoriasis business &, in general, areas where humira competes, has been and continues to be a relatively crowded market.AbbVie CEO, on conf call, says humira will still be a workhorse product within the psoriasis market, and risankizumab will fit in.AbbVie CEO, on conf call, says we would attempt to get a preliminary injunction to block any launches that violate our Humira IP ‍​.AbbVie, on conf call, says upadacitinib NDA next year will be filed with at least five of six studies ‍​.  Full Article

Abbvie reports Q3 adjusted earnings per share $1.41
Friday, 27 Oct 2017 07:40am EDT 

Oct 27 (Reuters) - Abbvie Inc ::Abbvie says Q3 earnings per share $1.01; Q3 adjusted earnings per share $1.41; Q3 net revenue $6,995 million versus $6,432 million.Abbvie says Q3 global humira net revenue $4.70 billion, up 15.8 percent on a reported basis.Q3 earnings per share view $1.38, revenue view $7.00 billion -- Thomson Reuters I/B/E/S.Abbvie says Q3 global imbruvica net revenue $688 million, up 37.3 percent on a reported basis.Abbvie says updates 2017 earnings per share guidance range to $4.27 to $4.29; raises 2017 adjusted earnings per share guidance range to $5.53 to $5.55.FY2017 earnings per share view $5.53 -- Thomson Reuters I/B/E/S.Abbvie says provides 2018 adjusted earnings per share guidance of $6.37 to $6.57.Fy2018 earnings per share view $6.56 -- Thomson Reuters I/B/E/S.Abbvie says on track to meet/exceed long-range guidance provided in Oct 2015; now expects 2020 global Humira sales to approach $21 billion.Announces a dividend increase of 11 percent, beginning with dividend payable in February 2018.2017 adjusted earnings per share outlook excludes $1.26 per share of intangible asset amortization expense, other items.  Full Article

Abbvie increases quarterly dividend by 11 percent
Friday, 27 Oct 2017 07:30am EDT 

Oct 27 (Reuters) - Abbvie Inc ::Abbvie increases quarterly dividend by 11 percent.Abbvie increases quarterly dividend by 11 percent.Sets quarterly cash dividend of $0.71 per share.  Full Article

Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix
Friday, 27 Oct 2017 07:00am EDT 

Oct 27 (Reuters) - Abbvie Inc :Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain.Abbvie inc - ‍expects PDUFA date for FDA to complete its review will be in Q2 2018​.  Full Article

AbbVie' Risankizumab meets all co-primary and ranked secondary endpoints
Thursday, 26 Oct 2017 08:02am EDT 

Oct 26 (Reuters) - Abbvie Inc :Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies.AbbVie - ‍Risankizumab safety profile consistent with that observed in phase 2 clinical trials, with no new safety signals detected across 3 studies​.AbbVie Inc - ‍In ultimma-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after last dose of study drug​.AbbVie Inc - ‍In ultimma-2, one patient receiving risankizumab died from a sudden cardiac arrest 101 days after last dose of study drug​.AbbVie Inc - ‍In ultimma-1 and ultimma-2, serious adverse events through week 16 occurred in 2 percent of patients on risankizumab in both studies​.AbbVie Inc - ‍In ultimma-2, a second patient receiving risankizumab died 161 days after last dose, with cause of death unknown​.AbbVie - ‍In immvent, serious adverse events occurred in 3 percent of patients in risankizumab group and 3 percent of patients in adalimumab group by week 16​.AbbVie Inc - ‍continuing to evaluate potential of risankizumab across several immune-mediated conditions​.AbbVie Inc - in immvent​, ‍one adalimumab patient was diagnosed with stage iv gallbladder cancer and died three weeks after diagnosis during study.AbbVie -a patient treated with risankizumab died of acute myocardial infarction on immvent study day 73; had past history of cardiovascular risk factors​.  Full Article

AbbVie says ‍Health Canada approved inclusion of nail Psoriasis data in humira product monograph​
Wednesday, 25 Oct 2017 08:00am EDT 

Oct 25 (Reuters) - Abbvie Inc :AbbVie Inc says ‍Health Canada has approved inclusion of Nail Psoriasis data in Humira product monograph​.  Full Article

Alector and AbbVie announce collaboration
Tuesday, 24 Oct 2017 07:00am EDT 

Oct 24 (Reuters) - AbbVie Inc :Alector and AbbVie announce collaboration to advance a novel class of immune therapies for patients with Alzheimer's disease.AbbVie Inc - ‍Alector and AbbVie will co-fund development and commercialization and will share global profits equally​.AbbVie Inc - ‍Alector will receive a $205 million upfront payment and a potential, future equity investment of up to $20 million​.  Full Article

Cerveau Technologies signs agreement with AbbVie for Novel Tau imaging agent
Monday, 23 Oct 2017 04:42am EDT 

Oct 23 (Reuters) - Cerveau Technologies Inc::Cerveau Technologies Inc signs license and supply agreement with AbbVie for Novel Tau imaging agent.Announced license and supply agreement with AbbVie for use of F-18MK-6240, an imaging agent to be used in PET scans​.  Full Article

Abbvie and harpoon therapeutics announce immuno-oncology research collaboration
Wednesday, 18 Oct 2017 08:30am EDT 

Oct 18 (Reuters) - Abbvie Inc :Abbvie and Harpoon Therapeutics announce immuno-oncology research collaboration.Abbvie Inc - ‍financial terms were not disclosed.​.Abbvie Inc - ‍under terms of agreement, Harpoon will engineer tritac molecules directed against selected cancer targets using its proprietary platform​.Abbvie Inc says Harpoon will ‍provide Abbvie right to pursue further development and commercialization of the tritac molecules​.Abbvie - collaboration to incorporate Harpoon's tritac platform with co's research-stage immuno-oncology targets to develop novel cancer therapeutics​.  Full Article

AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology
Tuesday, 10 Oct 2017 08:00am EDT 

Oct 10 (Reuters) - AbbVie Inc :AbbVie and Turnstone Biologics announce global collaboration on viral immunotherapies in oncology.AbbVie Inc - ‍AbbVie obtained an exclusive option to license up to three of Turnstone's next-generation oncolytic viral immunotherapies​.AbbVie Inc - ‍Abbvie has an option to obtain all global development and commercialization rights to Turnstone Biologics' Ad-MG1-MAGEA3 therapy​.AbbVie inc - ‍financial terms were not disclosed​.  Full Article

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.